Enveric Biosciences, Inc. (ENVB)
$
1.19
+0.09 (7.56%)
Key metrics
Financial statements
Free cash flow per share
-4.2 Thousand
Market cap
2.7 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
4.0821
Income quality
0.8083
Average inventory
0
ROE
-2.5028
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Enveric Biosciences, Inc., a pharmaceutical company headquartered in Naples, Florida, focuses on developing innovative cannabinoid medicines specifically for cancer care. The total costs and expenses for the company are -$9,632,266.00 reflecting its overall spending. The net income ratio is 0.00 indicating the company's profitability margin and ability to generate profits from its operations. Additionally, the operating income ratio stands at 0.00 which serves to indicate the company's operational profitability margin. The income before tax ratio is 0.00 reflecting the pre-tax margin and the company's efficiency in managing its revenue before it is taxed. Despite these metrics, the company reported a net loss of -$9,574,987.00 indicating challenges in its operations and the need for further strategic adjustments to improve its financial performance. The products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for addressing cancer-related distress; EVM-301 targeting mental health conditions; EV102, a topical cannabinoid cream; and EV101, a combination therapy involving cannabinoids and chemotherapy. In the financial landscape, Enveric Biosciences' stock is accessible at $1.34 making it suitable for budget-conscious investors looking for affordable investment opportunities. The stock has an average trading volume of 172,206.00 indicating moderate liquidity, which can appeal to investors seeking efficient entry and exit points. With a market capitalization of $2,941,275.00 the company is classified as a small-cap player within the financial markets. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its focused research and development initiatives. Furthermore, it belongs to the Healthcare sector, which drives innovation and growth, making it a noteworthy entity for anyone interested in the advancements in cannabinoid therapies for healthcare.
Is Enveric Biosciences, Inc. (ENVB) a good investment?
Investing in Enveric Biosciences, Inc. (ENVB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Enveric Biosciences, Inc. (ENVB)'s stock forecast?
Analysts predict Enveric Biosciences, Inc. stock to fluctuate between $1.01 (low) and $134.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Enveric Biosciences, Inc.'s market capitalization?
As of 2025-08-19, Enveric Biosciences, Inc.'s market cap is $2,941,275, based on 2,471,660 outstanding shares.
How does Enveric Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Enveric Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Enveric Biosciences, Inc. pay dividends?
Enveric Biosciences, Inc. pays dividends. The current dividend yield is 4.67%, with a payout of $0.00 per share.
How can I buy Enveric Biosciences, Inc. (ENVB) stock?
To buy Enveric Biosciences, Inc. (ENVB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENVB. Place an order (Market, Limit, etc.).
What is the best time to invest in Enveric Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Enveric Biosciences, Inc. stock ever split?
Enveric Biosciences, Inc.'s last stock split was 1:50 on 2022-07-15.
How did Enveric Biosciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$19.04 | Growth: 135.35%.
Where can I find Enveric Biosciences, Inc.'s investor relations reports?
Visit https://www.enveric.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Enveric Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Enveric Biosciences, Inc. stock?
All-time high: $2,805 (2021-09-10) | All-time low: $1.01 (2025-04-09).
What are the key trends affecting Enveric Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
6 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update. CEO Commentary “The second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with.
businesswire.com
a month ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent applic.
businesswire.com
a month ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive results in a preclinical, exposure-based therapeutic model for post-traumatic stress disorder (PTSD). In fear conditioned mice, oral administration of EB-003 significantly decreased context-induced freezing.
businesswire.com
2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activities. The 5-HT1B re.
businesswire.com
2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. During the conference, CEO and Director of Enveric, Joseph Tucker, Ph.D., will conduct one.
businesswire.com
2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were.
businesswire.com
3 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive preclinical results for its lead neuroplastogen drug candidate, EB-003, in the Open Space Forced Swim Test, a preclinical mouse model of severe depression and despair. The Open Space Forced Swim Test, a wel.
businesswire.com
3 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If c.
businesswire.com
3 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 was highlighted by continued progress in the development of EB-003, our neuroplastogenic.
businesswire.com
5 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported financial results for the fourth quarter and year ended December 31, 2024. “Enveric is entering 2025 with a clear miss.
See all news
